NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $30.62 +0.36 (+1.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$30.64 +0.02 (+0.08%) As of 08/29/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AMPH alerts:Sign Up Key Stats Today's Range$30.18▼$30.8150-Day Range$20.62▼$30.6252-Week Range$20.39▼$53.96Volume290,925 shsAverage Volume638,844 shsMarket Capitalization$1.42 billionP/E Ratio11.47Dividend YieldN/APrice Target$31.60Consensus RatingHold Company Overview Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Read More Amphastar Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreAMPH MarketRank™: Amphastar Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 333rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-5.73% Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to decrease by -5.73% in the coming year, from $3.49 to $3.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 268.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.11.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.79% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.7 / 5Environmental Score-2.21 Percentage of Shares Shorted11.79% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing. News and Social Media3.6 / 5News Sentiment1.45 News SentimentAmphastar Pharmaceuticals has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Amphastar Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,985.00 in company stock.Percentage Held by Insiders27.50% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPH Stock News HeadlinesFloyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockAugust 5, 2025 | insidertrades.comBank of America Forecasts Strong Price Appreciation for Amphastar Pharmaceuticals (NASDAQ:AMPH) StockAugust 28 at 2:52 AM | americanbankingnews.comHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best." | Brownstone Research (Ad)Analyzing Sol-Gel Technologies (NASDAQ:SLGL) & Amphastar Pharmaceuticals (NASDAQ:AMPH)August 27 at 2:45 AM | americanbankingnews.com5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings CallAugust 15, 2025 | msn.com05 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings CallAugust 14, 2025 | msn.comAmphastar Pharmaceuticals’ Mixed Earnings Call HighlightsAugust 13, 2025 | msn.comAmphastar stock gains after licensing deal for three peptide therapiesAugust 12, 2025 | investing.comSee More Headlines AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $37.13 on January 1st, 2025. Since then, AMPH stock has decreased by 17.5% and is now trading at $30.62. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Monday, November, 8th. The company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.24 by $0.22. The company had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a net margin of 18.64% and a trailing twelve-month return on equity of 20.76%. Read the conference call transcript. Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' top institutional shareholders include TD Asset Management Inc (4.32%), Epoch Investment Partners Inc. (2.67%), Boston Trust Walden Corp (2.50%) and Geode Capital Management LLC (2.06%). Insiders that own company stock include Mary Z Luo, Howard Lee, Rong Zhou, William J Peters, Floyd F Petersen, Yakob Liawatidewi, Richard K Prins and Michael A Zasloff. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/08/2021Today8/30/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMPH CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees2,028Year FoundedN/APrice Target and Rating Average Price Target for Amphastar Pharmaceuticals$31.60 High Price Target$36.00 Low Price Target$25.00 Potential Upside/Downside+3.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$2.67 Trailing P/E Ratio11.47 Forward P/E Ratio8.77 P/E GrowthN/ANet Income$159.52 million Net Margins18.64% Pretax Margin22.40% Return on Equity20.76% Return on Assets9.68% Debt Debt-to-Equity Ratio0.80 Current Ratio3.29 Quick Ratio2.21 Sales & Book Value Annual Sales$731.97 million Price / Sales1.94 Cash Flow$5.06 per share Price / Cash Flow6.05 Book Value$16.29 per share Price / Book1.88Miscellaneous Outstanding Shares46,490,000Free Float33,709,000Market Cap$1.42 billion OptionableOptionable Beta0.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AMPH) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.